Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503239 | 0.85 | KDM4E (0.45) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL18216628 | 0.85 | L3MBTL1 (0.55) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL22018876 | 0.83 | KDM4E (0.58) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL4053537 | 0.83 | KDM4E (0.54) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| Benzene SCHEMBL11818131 | 0.82 | KDM4E (0.70) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL353589 | 0.82 | KDM4E (0.70) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL21408838 | 0.81 | KDM4E (0.55) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL17746085 | 0.80 | KDM4E (0.68) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL27231741 | 0.80 | KDM4E (0.72) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 | |
| Acetic Acid SCHEMBL16667162 | 0.79 | KDM4E (0.66) | KDM4EMAPTCYP1A2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-103429589-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2013-12-04 | — | — | CN | claimed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | claimed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | claimed |
| CN-120202197-A | Nitrogen-containing spiro compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-117820199-A | Amide compound and application thereof in preparation of Sigma2 and 5HT2A inhibitors | 瀚远医药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2961749-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2014134341-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| CN-103429589-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2013-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 3126/4885MAPT 257/4885CYP1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.